http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#Head
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#assertion
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#provenance
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#pubinfo
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#assertion
http://purl.obolibrary.org/obo/DOID_10763
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_10763
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB09477
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#association
http://www.w3.org/2000/01/rdf-schema#label
epaned is an angiotensin converting enzyme inhibitor indicated for 1 1 1 2 1 3 epaned is indicated for the treatment of hypertension to lower blood pressure in adults and children older than one month see pediatric use 8 4 14 lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy epaned is effective alone or in combination with other antihypertensive agents especially thiazide type diuretics the blood pressure lowering effects of epaned and thiazides are approximately additive epaned is indicated for the treatment of symptomatic heart failure usually in combination with diuretics and digitalis in these patients epaned increases survival and decreases the frequency of hospitalization in clinically stable asymptomatic patients with left ventricular dysfunction ejection fraction 35 percent epaned decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB09477
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#provenance
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#pubinfo
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#sig
http://purl.org/nanopub/x/hasSignature
TKzT7A6NbF+yahoou2KhnqoErTz2RfbFwz4pPabMhpNwyhK4o8H0Sd1scTj+Jvddq1vuz7doligzpo+nBQBVlOvfVT/68PsfG7IILs43LvuQDxM7GSRCSvVadFqzv3QJ2q/tzEj6nINM8b29U3NXSt/IJAS4sxuUdtX2KT0W5bc=
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak
http://purl.org/dc/terms/created
2021-06-29T08:42:54.439+02:00
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAouDr9VDuuOn47HzLBBc-bzahmy0u_QeUPEtQ8vHFJak
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs